Cargando…

International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee

BACKGROUND: The Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention (TRS2°P), a 0‐to‐9‐point system based on the presence/absence of 9 clinical factors, was developed to classify the risk of major adverse cardiovascular events (MACE) (a composite of cardiovascular death,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mok, Yejin, Ballew, Shoshana H., Bash, Lori D., Bhatt, Deepak L., Boden, William E., Bonaca, Marc P., Carrero, Juan Jesus, Coresh, Josef, D'Agostino, Ralph B., Elley, C. Raina, Fowkes, F. Gerry R., Jee, Sun Ha, Kovesdy, Csaba P., Mahaffey, Kenneth W., Nadkarni, Girish, Peterson, Eric D., Sang, Yingying, Matsushita, Kunihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064832/
https://www.ncbi.nlm.nih.gov/pubmed/29982232
http://dx.doi.org/10.1161/JAHA.117.008426
_version_ 1783342761135570944
author Mok, Yejin
Ballew, Shoshana H.
Bash, Lori D.
Bhatt, Deepak L.
Boden, William E.
Bonaca, Marc P.
Carrero, Juan Jesus
Coresh, Josef
D'Agostino, Ralph B.
Elley, C. Raina
Fowkes, F. Gerry R.
Jee, Sun Ha
Kovesdy, Csaba P.
Mahaffey, Kenneth W.
Nadkarni, Girish
Peterson, Eric D.
Sang, Yingying
Matsushita, Kunihiro
author_facet Mok, Yejin
Ballew, Shoshana H.
Bash, Lori D.
Bhatt, Deepak L.
Boden, William E.
Bonaca, Marc P.
Carrero, Juan Jesus
Coresh, Josef
D'Agostino, Ralph B.
Elley, C. Raina
Fowkes, F. Gerry R.
Jee, Sun Ha
Kovesdy, Csaba P.
Mahaffey, Kenneth W.
Nadkarni, Girish
Peterson, Eric D.
Sang, Yingying
Matsushita, Kunihiro
author_sort Mok, Yejin
collection PubMed
description BACKGROUND: The Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention (TRS2°P), a 0‐to‐9‐point system based on the presence/absence of 9 clinical factors, was developed to classify the risk of major adverse cardiovascular events (MACE) (a composite of cardiovascular death, recurrent myocardial infarction, or ischemic stroke) among patients with a recent myocardial infarction. Its performance has not been examined internationally outside of a clinical trial setting. METHODS AND RESULTS: We evaluated the performance of TRS2°P for predicting MACE in 53 599 patients with recent myocardial infarction in 5 international cohorts from New Zealand, South Korea, Sweden, and the United States participating in the Chronic Kidney Disease Prognosis Consortium. Overall, there were 19 444 cases of MACE across 5 cohorts over a mean follow‐up of 5 years, and the overall MACE rate ranged from 5.0 to 18.4 (per 100 person‐years). The TRS2°P showed modest calibration (Brier score ranged from 0.144 to 0.173) and discrimination (C‐statistics >0.61 in all studies except 1 from Korea with 0.55) across cohorts relative to its original Brier score of 0.098 and C‐statistic of 0.67 in the derived data set. Although there was some heterogeneity across cohorts, the 9 predictors in the TRS2°P were generally associated with higher MACE risk, with strongest associations observed (meta‐analyzed adjusted hazard ratio 1.6–1.7) for history of heart failure, age ≥75 years, and prior stroke, followed by peripheral artery disease, kidney dysfunction, diabetes mellitus, and hypertension (hazard ratio 1.3–1.4). Prior coronary bypass graft surgery and smoking did not reach statistical significance (hazard ratio ≈1.1). CONCLUSIONS: TRS2°P, a simple scoring system with 9 routine clinical factors, was modestly predictive of secondary events when applied in patients with recent myocardial infarction from diverse clinical and geographic settings.
format Online
Article
Text
id pubmed-6064832
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60648322018-08-07 International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee Mok, Yejin Ballew, Shoshana H. Bash, Lori D. Bhatt, Deepak L. Boden, William E. Bonaca, Marc P. Carrero, Juan Jesus Coresh, Josef D'Agostino, Ralph B. Elley, C. Raina Fowkes, F. Gerry R. Jee, Sun Ha Kovesdy, Csaba P. Mahaffey, Kenneth W. Nadkarni, Girish Peterson, Eric D. Sang, Yingying Matsushita, Kunihiro J Am Heart Assoc Original Research BACKGROUND: The Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention (TRS2°P), a 0‐to‐9‐point system based on the presence/absence of 9 clinical factors, was developed to classify the risk of major adverse cardiovascular events (MACE) (a composite of cardiovascular death, recurrent myocardial infarction, or ischemic stroke) among patients with a recent myocardial infarction. Its performance has not been examined internationally outside of a clinical trial setting. METHODS AND RESULTS: We evaluated the performance of TRS2°P for predicting MACE in 53 599 patients with recent myocardial infarction in 5 international cohorts from New Zealand, South Korea, Sweden, and the United States participating in the Chronic Kidney Disease Prognosis Consortium. Overall, there were 19 444 cases of MACE across 5 cohorts over a mean follow‐up of 5 years, and the overall MACE rate ranged from 5.0 to 18.4 (per 100 person‐years). The TRS2°P showed modest calibration (Brier score ranged from 0.144 to 0.173) and discrimination (C‐statistics >0.61 in all studies except 1 from Korea with 0.55) across cohorts relative to its original Brier score of 0.098 and C‐statistic of 0.67 in the derived data set. Although there was some heterogeneity across cohorts, the 9 predictors in the TRS2°P were generally associated with higher MACE risk, with strongest associations observed (meta‐analyzed adjusted hazard ratio 1.6–1.7) for history of heart failure, age ≥75 years, and prior stroke, followed by peripheral artery disease, kidney dysfunction, diabetes mellitus, and hypertension (hazard ratio 1.3–1.4). Prior coronary bypass graft surgery and smoking did not reach statistical significance (hazard ratio ≈1.1). CONCLUSIONS: TRS2°P, a simple scoring system with 9 routine clinical factors, was modestly predictive of secondary events when applied in patients with recent myocardial infarction from diverse clinical and geographic settings. John Wiley and Sons Inc. 2018-07-07 /pmc/articles/PMC6064832/ /pubmed/29982232 http://dx.doi.org/10.1161/JAHA.117.008426 Text en © 2018 The Authors and Merck Sharpe & Dohme Corp. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Mok, Yejin
Ballew, Shoshana H.
Bash, Lori D.
Bhatt, Deepak L.
Boden, William E.
Bonaca, Marc P.
Carrero, Juan Jesus
Coresh, Josef
D'Agostino, Ralph B.
Elley, C. Raina
Fowkes, F. Gerry R.
Jee, Sun Ha
Kovesdy, Csaba P.
Mahaffey, Kenneth W.
Nadkarni, Girish
Peterson, Eric D.
Sang, Yingying
Matsushita, Kunihiro
International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee
title International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee
title_full International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee
title_fullStr International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee
title_full_unstemmed International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee
title_short International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee
title_sort international validation of the thrombolysis in myocardial infarction (timi) risk score for secondary prevention in post‐mi patients: a collaborative analysis of the chronic kidney disease prognosis consortium and the risk validation scientific committee
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064832/
https://www.ncbi.nlm.nih.gov/pubmed/29982232
http://dx.doi.org/10.1161/JAHA.117.008426
work_keys_str_mv AT mokyejin internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT ballewshoshanah internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT bashlorid internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT bhattdeepakl internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT bodenwilliame internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT bonacamarcp internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT carrerojuanjesus internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT coreshjosef internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT dagostinoralphb internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT elleycraina internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT fowkesfgerryr internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT jeesunha internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT kovesdycsabap internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT mahaffeykennethw internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT nadkarnigirish internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT petersonericd internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT sangyingying internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee
AT matsushitakunihiro internationalvalidationofthethrombolysisinmyocardialinfarctiontimiriskscoreforsecondarypreventioninpostmipatientsacollaborativeanalysisofthechronickidneydiseaseprognosisconsortiumandtheriskvalidationscientificcommittee